Seranova Bio utilizes proprietary REAP technology to analyze autoantibodies present in patient blood, revealing next-generation therapeutic candidates. This platform identifies protective autoantibodies that correlate with better disease outcomes in conditions like autoimmunity and cancer. The company then develops first-in-class therapeutics based on these naturally validated targets to improve patient health.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The role of autoantibodies in influencing disease outcomes is often overlooked due to technological limitations in identifying and analyzing these antibodies in patient blood samples. This lack of understanding hinders the development of targeted therapies that could leverage the protective effects of specific autoantibodies.
Solution
Seranova Bio employs its proprietary REAP (REactive AutoAntibody Profiling) technology to comprehensively analyze autoantibodies present in patient blood, effectively identifying naturally occurring clinical trials. By examining the correlation between specific autoantibody profiles and patient outcomes, Seranova uncovers potential therapeutic targets for autoimmune and autoantibody-driven diseases. This approach allows the company to develop first-in-class therapeutics that mimic the protective effects observed in patients with beneficial autoantibody responses, leading to improved treatment efficacy. The REAP technology overcomes previous limitations, providing a more accurate and extensive analysis of autoantibodies and their impact on disease.
Target Audience
Seranova's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for autoimmune and autoantibody-driven diseases.
Features
- REAP technology for high-throughput autoantibody profiling in patient samples
- Identification of "natural clinical trials" based on autoantibody reactivity and disease outcomes
- Target validation based on the protective effects of specific autoantibodies
- Development of first-in-class therapeutics that mimic beneficial autoantibody responses
- Application to autoimmune diseases, cancer, and neurodegenerative disorders